| Research purpose and backgroundThe International Agency for Research on Cancer(IARC)released the latest global cancer data for 2020.According to statistics,female breast cancer has become the most common cancer in the world[1].Therefore,it is of great value to study the mechanism of breast cancer and actively seek new biomarkers related to the clinical characteristics and prognosis of breast cancer.In cancer cells,one of the most important metabolic abnormalities is an increase in lipid synthesis,the building blocks of cell membrane formation during cell proliferation and signaling molecule transmission.Studies have shown that abnormal de novo lipid synthesis and reprogrammed lipid metabolism are related to the occurrence and development of various cancers(including breast cancer),and dysregulation of lipid metabolism is a key factor in the malignant transformation of breast cancer[2,3].Lipogenic enzymes are often overexpressed in many cancer types[4].Cdp-diacylglycerol synthase(CDS-Diacylglycerol synthase)catalyzes the conversion of phospholipid acid(PA)into CDS-DIacylglycerol(CDS-DAG).CDS1 and CDS2 are only identified as two types of CDS in mammals.Studies have shown that CDS1 is more important for adipogenesis,and previous studies have shown that CDS1 is related to the occurrence and development of cancer[5],but its specific role in promoting or inhibiting cancer is unknown[6].The purpose of this study is to clarify the expression of CDS1 in breast cancer,its relationship with prognosis and its possible signaling pathways.The research methodsPublic bioinformation database was used to analyze the expression of CDS1 in breast cancer tissues,and then the correlation between CDS1 and prognosis was analyzed.GO and KEGG enrichment analysis was performed to explore the signaling pathway that CDS1 might be involved in.Immunohistochemical staining was used to detect the difference of CDS 1 protein expression levels in tissues microarray containing 85 cases of 170 sites of breast cancer and adjacent tissues(normality test and non-parametric test statistical methods).The correlation between them and clinicopathological features was analyzed(Chi-square test statistical method).Finally,survival analysis was performed(Log-rank test and Kaplan-Meier survival curve was drawn).Results1.Bioassay results showed that CDS1 expression in breast cancer tissues was higher than that in normal breast tissues,and patients with high CDS1 expression had a poor prognosis(P=0.0023).The results of enrichment analysis showed that the differential genes in breast cancer were mainly concentrated in the regulation pathway of lipid metabolism,PI3K-Akt signaling pathway and the regulation pathway of lipolysis function in adipocytes and other pathways.2.Immunohistochemical staining results showed that the expression level of CDS1 in breast cancer tissues was higher than that in adjacent tissues(P=0.000),and the staining rate of cancer tissue was higher than that of adjacent tissue(P=0.012).The chromogenic rate of CDS 1 was high when Ki-67 was highly expressed(P=0.030).Although the results of survival analysis showed no significant correlation between CDS1 and prognosis of breast cancer(P=0.718,with a small number of end-point events),the trend of survival curve also indicated that patients with high CDS1 expression had a poor prognosis.ConclusionThe expression of CDS1 in breast cancer tissues was significantly higher than that in adjacent tissues,which was positively correlated with the high expression of Ki-67.Survival curve showed that patients with high expression of CDS1 tended to have a poor prognosis.Therefore,we believe that CDS1 is an oncogene with research value in breast cancer,and may promote the occurrence and development of breast cancer by participating in lipid metabolism regulation pathway,PI3K-Akt signaling pathway,regulation pathways of lipolysis in adipocytes and other pathways. |
PDF Full Text Request